If You Invested in Lakewood-Amedex Biotherapeutics Inc. (LABT)
Looking for the current price? See the LABT quote & overviewWhat $1,000 or $10,000 in LABT Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Apr 23, 2026 |
|---|---|---|---|---|
| $1,000 | — | — | — | $2.14 -99.79% |
| $10,000 | — | — | — | $21 -99.79% |
Based on real historical closing prices adjusted for stock splits, without dividends, through the latest market close. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for LABT$1,000 Investment Over Time
LABT vs S&P 500Year-by-Year Returns
LABT annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2026Apr 23, 2026 to Nov 2, 2026 | $86.50 | $0.1850 | -99.8% | -99.8% |
About Lakewood-Amedex Biotherapeutics Inc.
Healthcare · NASDAQ
Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotechnology company developing antimicrobial drug candidates for infectious diseases. The company’s research is centered on the Bisphosphocin® class, a novel class of fast-acting, broad-spectrum antimicrobials discovered by Lakewood-Amedex and intended to address bacterial infections, including strains associated with antimicrobial resistance such as MRSA and VRE. Its common stock trades on the Nasdaq Capital Market under the symbol LABT following an April 2026 direct listing.
Antimicrobial platform and lead compound
The company’s lead compound, Nu-3, is being developed as a topically delivered antimicrobial treatment for infected diabetic foot ulcers. Lakewood-Amedex describes Nu-3 as part of its Bisphosphocin platform. Reported in vitro data for the class indicate rapid bacterial killing through pH- and concentration-dependent destabilization of bacterial cell membranes. The platform is also being explored in preclinical studies for potential use in complicated urinary tract infection and pulmonary infections.
Lakewood-Amedex’s operating model is based on advancing proprietary antimicrobial compounds through research, preclinical work, clinical development, and regulatory preparation. As a clinical-stage biotechnology issuer, the company’s durable business profile is defined by its drug-development pipeline rather than commercial product sales.
Public company status
Lakewood-Amedex Biotherapeutics is incorporated in Nevada and maintains principal executive offices in University Park, Florida. Its SEC registration materials identify the company within pharmaceutical preparations. Public-company disclosures for LABT cover securities registration, corporate governance, board composition, capital structure, business risks, and updates related to its antimicrobial development programs.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Lakewood-Amedex Biotherapeutics Inc. investment returns
How much would $1,000 invested in Lakewood-Amedex Biotherapeutics Inc. be worth today?
Limited historical data is available for LABT. Our price data for LABT starts on Apr 23, 2026.
Has Lakewood-Amedex Biotherapeutics Inc. outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare LABT performance over available time periods.
For informational and educational purposes only, not investment advice.
